Wuhan Zhongzhi Biotechnologies INC. (ZBI), located in Wuhan, China, was founded in 2011. As a national High-Tech enterprise, ZBI provides customers with multiplex and rapid molecular diagnostic reagents, supporting instruments, and comprehensive nucleic acid detection solutions.

ZBI is the exclusive domestic innovative enterprise for multiplex detection and rapid detection of nucleic acid RNA pathogens, is an important security enterprise for epidemic prevention and control in Hubei, and an important enterprise for the production of medical epidemic prevention materials in Wuhan. At the beginning of the Covid-19 breakthrough, ZBI, as a representative molecular diagnostic enterprise in Hubei, first developed two 2019-nCoV nucleic acid detection kits based on RNA technology platforms, which were approved by NMPA.